Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

5.320 +0.410 (+8.35%)
Streaming Delayed Price Updated: 12:18 PM EST, Mar 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 157,224
Open 4.880
Bid (Size) 5.200 (100)
Ask (Size) 5.330 (100)
Prev. Close 4.910
Today's Range 4.820 - 5.550
52wk Range 3.920 - 19.14
Shares Outstanding 101,102,152
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ATRA Rises On Pushing For Meeting With FDA On Rare Disease Drug Rejection ↗
FDA refused approval for tabelecleucel in treating patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease earlier this year. 
Via Stocktwits
News headline image
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
From Atara Biotherapeutics, Inc.
Via Business Wire

Performance

YTD
-70.1%
-70.1%
1 Month
+5.6%
+5.6%
3 Month
-60.7%
-60.7%
6 Month
-56.9%
-56.9%
1 Year
-24.0%
-24.0%

More News

Read More
News headline image
Atara Biotherapeutics Provides a Business Update
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
FDA Reversal Sends Atara Biotherapeutics into Tailspin: Stock Plummets 67% on Second CRL for Tabelecleucel
Via MarketMinute
Topics Bankruptcy
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
Keep an eye on the top gainers and losers in Tuesday's session. ↗
Via Chartmill
Unusual volume stocks are being observed in Tuesday's session. ↗
Via Chartmill
Keep an eye on the top gainers and losers in Monday's session. ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
News headline image
ATRA Stock Nearly Halves In Value After FDA Refuses Approval For Immunotherapy: Retail Sees ‘Big Fight Back’ ↗
Via Stocktwits
Gapping stocks in Monday's session ↗
Via Chartmill
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Small-Cap Renaissance: Russell 2000 Scales New Heights While Big Tech Stumbles
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Small-Cap Slump: Russell 2000 Tumbles as Sticky Inflation Data Revives 'Higher-for-Longer' Fears
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗
Via Benzinga
News headline image
Atara Biotherapeutics Announces Changes to Its Board of Directors
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)
From Atara Biotherapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Atara Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Atara Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Atara Biotherapeutics, Inc. - Common Stock trade on?
Atara Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Atara Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Atara Biotherapeutics, Inc. - Common Stock is ATRA on the Nasdaq Stock Market
What is the current price of Atara Biotherapeutics, Inc. - Common Stock?
The current price of Atara Biotherapeutics, Inc. - Common Stock is 5.320
When was Atara Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Atara Biotherapeutics, Inc. - Common Stock was at 03/03/26 12:18 PM ET
What is the market capitalization of Atara Biotherapeutics, Inc. - Common Stock?
The market capitalization of Atara Biotherapeutics, Inc. - Common Stock is 537.86M
How many shares of Atara Biotherapeutics, Inc. - Common Stock are outstanding?
Atara Biotherapeutics, Inc. - Common Stock has 538M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.